- ImmunoGen Inc. announced positive results from its trial of mirvetuximab soravtansine in ovarian cancer.
- Notably, the SORAYA trial met its primary endpoint with a confirmed objective response rate of 32.4%.
The company said it aims to complete the Biologics License Application for mirvetuximab, its potential treatment for patients with platinum-resistant ovarian cancer, by submitting an application to the Food and Drug Administration for accelerated approval in the first quarter of 2022.
Mark Enyedy, ImmunoGen's president and CEO, said it is an "exciting moment, both for the field of ovarian cancer and for ImmunoGen," with the outcomes from the SORAYA trial "further validate our longstanding history of innovation in ADCs."
"Commercial preparations are well underway to support the potential launch of mirvetuximab next year," he added.
No comments:
Post a Comment